Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Low levels of sex hormone-binding globulin predict an increased breast cancer risk and its underlying molecular mechanisms.Open life sciences · 2024
   Review
2. A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape.Journal of translational medicine · 2021
   Article
3. Loss of ZIP facilitates JAK2-STAT3 activation in tamoxifen-resistant breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2020
   Article
4. Development and characterisation of acquired radioresistant breast cancer cell lines.Radiation oncology (London, England) · 2019
   Article
5. Targeting the insulin growth factor receptor 1.Hematology/oncology clinics of North America · 2012
   Review
6. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.BMC cancer · 2011
   Article
7. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.Breast cancer research and treatment · 2010
   Article
8. IGF and insulin receptor signaling in breast cancer.Journal of mammary gland biology and neoplasia · 2008
   Article
9. Transgenic models to study actions of prolactin in mammary neoplasia.Journal of mammary gland biology and neoplasia · 2008
   Review
10. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.Reviews in endocrine & metabolic disorders · 2007
    Review
11. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.Oncogene · 2005
    Article
12. Roles for neuregulins in human cancer.Clinical & experimental metastasis · 2004
    Review
13. Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer.Breast cancer research : BCR · 2004
    Article
14. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells.Oncogene · 2001
    Article
15. Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.Molecular medicine (Cambridge, Mass.)
    Article
16. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.The Journal of steroid biochemistry and molecular biology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as